Oxaliplatin-based chemotherapy

Phase 1Small molecule

Oxaliplatin-based chemotherapy is one of 34 small molecule programs targeting Neuroendocrine Tumors. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Neuroendocrine TumorsCompleted

NeuropathyRecruiting

Neuroendocrine TumorsPreclinical

Completed

NeuropathyPhase 1

Recruiting

Competition

Competitive Landscape

24 competitors in Neuropathy

#DrugCompanyPhaseTrials

Elavil

AstraZeneca

Approved

—2

Lyrica

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

3 3

Accupril

Pfizer

Approved

1 4

Pamelor

SSpecgx

Approved

1 5

Mexitil

Boehringer Ingelheim

Approved

1 6

Epsom Salt

FFresenius Kabi USA, LLC

Immunoglobulin

4 8

Rituxan

Roche

Phase 2

2 9

Calquence

AstraZeneca

Phase 2

1 10

Calciferol

Jazz Pharmaceuticals

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Phase 1Recruiting

Neuropathy

NCT07167446

Clinical

Trials by Indication[1]

Neuroendocrine Tumors1 trial

MGMT-NET: O6-methylguanine-DNA Methyltransferase (MGMT) Status in Neuroendocrine Tumors: Predictive Factor of Response to Alkylating Agents

Completed·HHospices Civils de Lyon·N/A·NCT03217097·116 enrolled

Colorectal Cancer1 trial

PACCE: Panitumumab Advanced Colorectal Cancer Evaluation Study

Completed· Amgen logo

Amgen·Phase 3·NCT00115765·1,053 enrolled

Lymphoma1 trial

Etoposide, Methylprednisolone, High-dose Cytarabine and Oxaliplatin (ESHAOx) for Refractory or Relapsed Hodgkin's Lymphoma (HL)

Unknown status·NNational Cancer Center, Korea·Phase 2·NCT01300156·37 enrolled

Intestinal Cancer1 trial

Monosialotetrahexosylganglioside for Treatment of Oxaliplatin Induced Neurotoxicity in Gastrointestinal Cancer

Completed·TTianjin Medical University Cancer Institute and Hospital·Phase 3·NCT02486198·145 enrolled

Neuropathy1 trial

Neuroprotective Potential of Cannabidiol (CBD) in Preventing Oxaliplatin (Ox)-Induced Neuropathy

Recruiting·FFox Chase Cancer Center·Phase 1·NCT07167446·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Oxaliplatin-based chemotherapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Oxaliplatin-based chemotherapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Oxaliplatin-based chemotherapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Amgen company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: Amgen

Oxaliplatin-based chemotherapy

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2028

Trials by Indication[1]

Neuroendocrine Tumors1 trial

Colorectal Cancer1 trial

Lymphoma1 trial

Intestinal Cancer1 trial

Neuropathy1 trial

References

Drug Info

Quick Facts

Related News